Checkpoint Inhibitors news and latest updates

Latest Posts

msd avelumab pdl1 immunooncology pfizer etinostat

News and Trends 5 Jan 2016

How these Latest Trials Prove PD-L1 as The Breakthrough Trend in Immuno-Oncology that is Here to Stay…

By targeting platinum resistant Ovarian cancer, Avelumab is a new anti-PD-L1 checkpoint inhibitor on the Cancer block. This just affirms how PD-L1 receptor is seen as the current breakthrough therapeutic target in Immuno-Oncology. Program-Death ligand 1 (PD-L1) is already a common target for mAbs in immuno-oncology. If expressed on the tumor cells, this enables the […]

January 5, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 24 Nov 2015

Money Money Money for Immuno-Oncology: BMS Joins up with a Top German VC

The World Leader in the Immuno-Oncology field has teamed up with a major German Investor to better identify breakthrough investment opportunities across the EU. Bristol-Myers Squibb (BMS) has partnered with Life Sciences Partners in Munich to highlight novel immuno-oncology technologies which could be the next blockbusters in the field. Together the two have conspired a […]

November 24, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Sep 2015

Will Roche lose its Worldwide Leading position in Cancer treatments?

Roche is the worldwide leader in cancer treatments, but it’s threatened by the increasing competition of biosimilars and the development of next-generation cancer drugs. Is there a risk for the “biggest Biotechnology company worldwide” to lose its leading position on the lucrative anti-cancer business? The Swiss giant makes massive amount of cash with its cancer treatments, […]

September 29, 2015 - 4 minutesmins - By Philip Hemme

News and Trends 12 Aug 2015

Roche and Clovis combine drugs to fight lung cancer, the most common cancer worldwide

Roche‘s subsidiary Genentech joined forces with NASDAQ-listed Clovis Oncology to evaluate a novel combination therapy for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). Its anti PD-L1 cancer immunotherapy and Clovis’ rociletinib will enter Phase Ib/II in 2015. With 1.35 million new cases annually, lung cancer is the most common cancer worldwide. In […]

August 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 21 Jul 2015

BMS steps into the European Market with its new Lung Cancer Treatment

It’s the first major treatment for metastatic squamous non-small cell lung cancer (NSCLC) to have been approved in over a decade in Europe: Bristol-Myers Squibb’s PD-1 immune checkpoint inhibitor Nivolumab was granted with market authorization by the European Commission. The drug is the first to improve overall survival in previously-treated metastatic NSCLC. Just one month […]

July 21, 2015 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us